The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population)

被引：0
|
作者：
Jaeger, M.
Schoberth, A.
Hennig, M.
Burges, A.
Heiss, M.
Wimberger, P.
Schmalfeldt, B.
Lindhofer, H.
机构：
[1] TRION Res GmbH, Martinsried, Germany
[2] Fresenius Biotech GmbH, Munich, Germany
[3] Univ Munich, Dept Gynecol & Obstet, Munich, Germany
[4] Univ Cologne Witten Herdecke, Dept Surg, Cologne, Germany
[5] AGO, Essen, Germany
[6] AGO, Munich, Germany
[7] TRION Pharma GmbH, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites
    Jaeger, M.
    Schoberth, A.
    Hennig, M.
    Burges, A.
    Heiss, M.
    Wimberger, P.
    Schmalfeldt, B.
    Lindhofer, H.
    ONKOLOGIE, 2010, 33 : 158 - 158
  • [2] Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites
    Jaeger, M. J.
    Schoberth, A. M.
    Heiss, M. M.
    Lahr, A.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3)
    Jaeger, Michael
    Schoberth, Alexandra
    Ruf, Peter
    Hess, Juergen
    Hennig, Michael
    Schmalfeldt, Barbara
    Wimberger, Pauline
    Stroehlein, Michael
    Theissen, Bettina
    Heiss, Markus M.
    Lindhofer, Horst
    CANCER RESEARCH, 2012, 72 (01) : 24 - 32
  • [4] Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study.
    Sebastian, M.
    Schuette, W.
    Schneller, F.
    Nilius, G.
    Lodziewski, S.
    Passlick, B.
    Hoffken, G.
    Friccius-Quecke, H.
    Jaeger, M.
    Schmittel, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 112S - 112S
  • [5] Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM x Anti-CD3) Results of a Phase 1/2 Study
    Sebastian, Martin
    Kiewe, Philipp
    Schuette, Wolfgang
    Brust, Daniel
    Peschel, Christian
    Schneller, Folker
    Ruehle, Karl-Heinz
    Nilius, Georg
    Ewert, Ralf
    Lodziewski, Sven
    Passlick, Bernward
    Siene, Wulf
    Wiewrodt, Rainer
    Jaeger, Michael
    Lindhofer, Horst
    Friccus-Quecke, Hilke
    Schmittel, Alexander
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) : 195 - 202
  • [6] Catumaxomab - trifunctional anti-EpCAM antibody used to treat malignant ascites
    Bokemeyer, Carsten
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (08) : 1259 - 1269
  • [7] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
    Burges, Alexander
    Wimberger, Pauline
    Kuemper, Carolin
    Gorbounova, Vera
    Sommer, Harald
    Schmalfeldt, Barbara
    Pfisterer, Jacobus
    Lichinitser, Michail
    Makhson, Anatoliy
    Moiseyenko, Vladimir
    Lahr, Angelika
    Schulze, Elisabeth
    Jaeger, Michael
    Stroehlein, Michael A.
    Heiss, Markus Maria
    Gottwald, Thomas
    Lindhofer, Horst
    Kimmig, Rainer
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3899 - 3905
  • [8] Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
    P Wimberger
    A Burges
    V Gorbounova
    H Sommer
    B Schmalfeldt
    J Pfisterer
    M Lichinitser
    A Makhson
    M Ströhlein
    W Eiermann
    M Biakhov
    V Moiseenko
    A du Bois
    R Kimmig
    Cancer Cell International, 4 (Suppl 1)
  • [9] Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Seimetz, Diane
    Lindhofer, Horst
    Bokemeyer, Carsten
    CANCER TREATMENT REVIEWS, 2010, 36 (06) : 458 - 467
  • [10] Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion
    Sebastian, M.
    Jaeger, M.
    Kiewe, P.
    Schuette, W.
    Wiewrodt, R.
    Lindhofer, H.
    Mueller, B.
    Friccius-Quecke, H.
    Friccius-Quecke, H.
    Schmittel, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345